Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

The trial design here is important.

As discussed by the Company in previous video communications...

The South Korea trial is looking at patients already on mechanical ventilation. These patients might not be as salvageable. They might be too far gone. And there is fewer of them.

The Canada trial is treating patients BEFORE they end up on ventilator. This means WAY MORE ELIGIBLE PATIENTS.

Also they state they are going to be submitting for trial approval and US FDA and Australia.